Expect significant selling pressure as four major institutional holders (Longitude, Montanova, SR One, J.W. Childs) are registering their entire stakes for resale. Monitor for any large block trades in the coming days/weeks. The company's recent $108.65 close may face downward pressure as overhang materializes. No specific offer price or timing details are provided, but the 120-day effectiveness period with potential extensions creates near-term overhang.
Executive Summary
Veradermics filed an S-1 registration statement for the resale of up to 17,072,058 shares of common stock (including 300,000 shares on exercise of pre-funded warrants) by selling stockholders, representing approximately 40.6% of total outstanding shares as of June 30, 2026. The company will not receive any proceeds from these sales, only from potential cash exercises of the warrants. This filing creates significant overhang risk as major institutional holders including Longitude Capital, Montanova Capital, SR One, and J.W. Childs Associates register their entire positions for sale.
Key Facts
- Selling stockholders registering up to 16,772,058 common shares plus 300,000 shares underlying pre-funded warrants for resale
- Resale shares represent ~40.6% of total outstanding common stock as of June 30, 2026
- Company receives no proceeds from resale of shares by selling stockholders
- Major selling stockholders include entities affiliated with Longitude Capital (4,653,873 shares), Montanova Capital (4,468,970 shares), SR One (2,401,868 shares), and J.W. Childs Associates (2,202,006 shares)
- Last reported sale price on August 6, 2026: $108.65 per share
- Maximum aggregate offering price calculated at ~$1.7 billion based on $99.39 average price
- Company closed a $30.0 million private placement in May 2026 with Montanova Capital affiliates involving pre-funded warrants at $99.99999 per warrant
Financial Impact
Up to ~$1.7 billion in potential selling pressure at the reference price of ~$99.39 per share, representing 40.6% of outstanding shares registered for resale
Risk Factors
- Massive secondary share overhang of 40.6% of outstanding shares registered for resale
- No company proceeds from primary share sales means no positive catalyst to offset dilution
- Potential for accelerated selling by large institutional holders exiting positions simultaneously
- Late clinical-stage biopharma with no approved products or revenue - stock largely driven by clinical trial catalysts and sentiment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001628280-26-054921 |
| Exhibit: exfilingfees.htm | 0001628280-26-054921 |
| Exhibit: exhibit51-sx1august2026.htm | 0001628280-26-054921 |
| Exhibit: exhibit231-sx1august2026.htm | 0001628280-26-054921 |
| Document: 0001628280-26-054921-index-headers.html | 0001628280-26-054921 |
| Document: 0001628280-26-054921-index.html | 0001628280-26-054921 |
| Document: 0001628280-26-054921.txt | 0001628280-26-054921 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $122.28 | awaiting T+5 | — | $138.23 (+13.04%) |
Oct 13, 2026 12d ago | SC 13G | $116.26 $127.11 | ▲ +9.33% | ▲ +10.48% | $138.23 (+18.90%) |
Aug 21, 2026 9w ago | Insider Cluster | $98.46 $98.41 | ▲ +0.05% | ▲ +0.52% | $138.23 (−40.39%) |
Aug 20, 2026 9w ago | 3 | $102.82 $97.93 | ▼ −4.76% | ▼ −5.23% | $138.23 (+34.44%) |
Aug 18, 2026 9w ago | Insider Cluster | $111.23 $102.80 | ▼ −7.58% | ▼ −7.19% | $138.23 (+24.27%) |
Aug 11, 2026 10w ago | 8-K | $110.75 $111.31 | ▲ +0.51% | ▲ +0.91% | $138.23 (+24.81%) |
Aug 7, 2026 11w ago | S-1 | $110.75 $108.22 | ▲ +2.28% | ▲ +2.24% | $138.23 (−24.81%) |
Aug 7, 2026 11w ago | Institutional Cluster | $114.39 $112.71 | ▼ −1.47% | ▼ −1.87% | $138.23 (+20.84%) |
Jul 15, 2026 14w ago | 8-K | $123.70 $109.85 | ▼ −11.20% | ▼ −10.22% | $138.23 (+11.75%) |
May 12, 2026 23w ago | 8-K | $103.90 $100.38 | ▼ −3.39% | ▼ −3.47% | $138.23 (+33.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers